UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2003
BIOSANTE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-28637 |
|
58-2301143 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
|
111 Barclay Boulevard Lincolnshire, Illinois |
|
60069 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(847) 478-0500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, If Changed Since Last Report)
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not Applicable
(b) Pro Forma Financial Information.
Not Applicable
(c) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
Ex. 99.1 |
|
Press Release dated August 14, 2003 (filed herewith electronically). |
Item 12. Results of Operations and Financial Condition.
On August 14, 2003, BioSante issued a press release announcing BioSante’s second quarter 2003 financial results of operations and financial condition. Attached hereto as Exhibit 99.1 is a copy of BioSante’s press release dated August 14, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOSANTE PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Phillip B. Donenberg |
|
|
|
|
|
Phillip B. Donenberg |
|
||
|
|
|
Chief Financial Officer, Treasurer and Secretary |
|
||
|
|
|
|
|
||
|
Dated: August 14, 2003 |
|
|
|||
2
BIOSANTE PHARMACEUTICALS, INC.
FORM 8-K
Exhibit Index
|
Exhibit |
|
Description |
|
Method of Filing |
|
99.1 |
|
Press Release of BioSante Pharmaceuticals, Inc. issued August 14, 2003 |
|
Filed herewith |
3